Mikrobiomik Pipeline

MBK-001

Our first product is a biopharmaceutical Involving TFM (Total Fecal Microbiota) technology that is available as lyophilised oral capsules of faecal microbiota, designed for treating recurrent CDI (R-CDI), in a simple dose of four capsules taken on a single occasion.

PHASE III

We have submitted our first product, MBK-001 (lyophilised capsules of faecal microbiota) for approval by AEMPS (Spanish Agency for Medicines and Health Products) for its multicentre, randomised, controlled and open phase III clinical trial on patients with R-CDI to assess the performance and safety of lyophilised capsules of faecal microbiota vs fidaxomicin.